Gambogic acid inhibits osteoclast formation and ovariectomy-induced osteoporosis by suppressing the JNK, p38 and Akt signalling pathways

Biochemical Journal

Volumn 469, Issue 3, 2015, Pages 399-408

  Ma, Jianjun ^a   Ma, Yan ^a   Liu, Xuqiang ^b   Chen, Shuai ^a   Liu, Chao ^a   Qin, An ^b   Fan, Shunwu ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Akt; Gambogic acid; JNK; Osteoclasts; Osteoporosis; P38

Indexed keywords

ADENOSINE TRIPHOSPHATASE; CATHEPSIN K; COLONY STIMULATING FACTOR 1; GAMBOGIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C FOS; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; ONCOPROTEIN; XANTHONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE DENSITY; BONE MASS; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; GENE EXPRESSION; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OVARIECTOMY-INDUCED OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL DIFFERENTIATION; CYTOLOGY; DOWN REGULATION; DRUG EFFECTS; ENZYMOLOGY; GENETICS; HUMAN; METABOLISM; OSTEOPOROSIS; OVARIECTOMY;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; DOWN-REGULATION; FEMALE; HUMANS; MAP KINASE KINASE 4; MICE; MICE, INBRED C57BL; ONCOGENE PROTEIN V-AKT; OSTEOCLASTS; OSTEOPOROSIS; OVARIECTOMY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANK LIGAND; SIGNAL TRANSDUCTION; XANTHONES;

EID: 84938375914     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20150151     Document Type: Article

References (38)

1. Udagawa, N., Takahashi, N., Akatsu, T., Tanaka, H., Sasaki, T., Nishihara, T., Koga, T., Martin, T.J. and Suda, T. (1990) Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. U.S.A. 87, 7260-7264 CrossRef PubMed
2. Manolagas, S.C. and Jilka, R.L. (1995) Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332, 305-311 CrossRef PubMed
3. Sato, K. and Takayanagi, H. (2006) Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr. Opin. Rheumatol. 18, 419-426 CrossRef PubMed
4. Greenfield, E.M., Bi, Y., Ragab, A.A., Goldberg, V.M. and Van De Motter, R.R. (2002) The role of osteoclast differentiation in aseptic loosening. J. Orthop. Res. 20, 1-8 CrossRef PubMed
5. Roodman, G.D. (1995) Osteoclast function in Paget's disease and multiple myeloma. Bone 17 (Suppl.), 57S-61S CrossRef PubMed
6. Clohisy, D.R. and Ramnaraine, M.L. (1998) Osteoclasts are required for bone tumors to grow and destroy bone. J. Orthop. Res. 16, 660-666 CrossRef PubMed
7. Dempster, D.W., Lambing, C.L., Kostenuik, P.J. and Grauer, A. (2012) Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. Clin. Ther. 34, 521-536 CrossRef PubMed
8. Qaseem, A., Snow, V., Shekelle, P., Hopkins, R.J., Forciea, M.A. and Owens, D.K. (2008) Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 149, 404-415 CrossRef PubMed
9. Wysowski, D.K. (2009) Reports of esophageal cancer with oral bisphosphonate use. N. Engl. J. Med. 360, 89-90 CrossRef PubMed
10. Salesi, N., Pistilli, R., Marcelli, V., Govoni, F.A., Bozza, F., Bossone, G., Venturelli, V., Di Cocco, B., Pacetti, U., Ciorra, A. et al. (2006) Bisphosphonates and oral cavity avascular bone necrosis: a review of twelve cases. Anticancer Res. 26, 3111-3115 PubMed
11. Suresh, E., Pazianas, M. and Abrahamsen, B. (2014) Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) 53, 19-31 CrossRef PubMed
12. Bitto, A., Burnett, B.P., Polito, F., Marini, H., Levy, R.M., Armbruster, M.A., Minutoli, L., Di Stefano, V., Irrera, N., Antoci, S. et al. (2008) Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. Br. J. Pharmacol. 155, 896-905 CrossRef PubMed
13. null T cells and B lymphopoesis in ovariectomized mice: a key mechanism for anti-osteoclastogenic effect. PLoS One 6, e21216 CrossRef PubMed
14. 2 synthesis. Phytomedicine 18, 176-185 CrossRef PubMed
15. Xue, L., Jiao, L., Wang, Y., Nie, Y., Han, T., Jiang, Y., Rahman, K., Zhang, Q. and Qin, L. (2012) Effects and interaction of icariin, curculigoside, and berberine in er-xian decoction, a traditional Chinese medicinal formula, on osteoclastic bone resorption. Evid. Based Complement. Alternat. Med. 2012, 490843 PubMed
16. Han, Q.B., Cheung, S., Tai, J., Qiao, C.F., Song, J.Z. and Xu, H.X. (2005) Stability and cytotoxicity of gambogic acid and its derivative, gambogoic acid. Biol. Pharm. Bull. 28, 2335-2337 CrossRef PubMed
17. Wu, Z.Q., Guo, Q.L., You, Q.D., Zhao, L. and Gu, H.Y. (2004) Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. Biol. Pharm. Bull. 27, 1769-1774 CrossRef PubMed
18. Pandey, M.K., Sung, B., Ahn, K.S., Kunnumakkara, A.B., Chaturvedi, M.M. and Aggarwal, B.B. (2007) Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor-κB signaling pathway. Blood 110, 3517-3525 CrossRef PubMed
19. Qi, Q., You, Q., Gu, H., Zhao, L., Liu, W., Lu, N. and Guo, Q. (2008) Studies on the toxicity of gambogic acid in rats. J. Ethnopharmacol. 117, 433-438 CrossRef PubMed
20. Wang, L.H., Yang, J.Y., Yang, S.N., Li, Y., Ping, G.F., Hou, Y., Cui, W., Wang, Z.Z., Xiao, W. and Wu, C.F. (2014) Suppression of NF-κB signaling and P-glycoprotein function by gambogic acid synergistically potentiates adriamycin-induced apoptosis in lung cancer. Curr. Cancer Drug Targets 14, 91-103 CrossRef PubMed
21. Ouyang, Z., Zhai, Z., Li, H., Liu, X., Qu, X., Li, X., Fan, Q., Tang, T., Qin, A. and Dai, K. (2014) Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway. Biochem. Pharmacol. 90, 276-287 CrossRef PubMed
22. Liu, X., Qu, X., Wu, C., Zhai, Z., Tian, B., Li, H., Ouyang, Z., Xu, X., Wang, W., Fan, Q. et al. (2014) The effect of enoxacin on osteoclastogenesis and reduction of titanium particle-induced osteolysis via suppression of JNK signaling pathway. Biomaterials 35, 5721-5730 CrossRef PubMed
23. Qu, X., Zhai, Z., Liu, X., Li, H., Ouyang, Z., Wu, C., Liu, G., Fan, Q., Tang, T., Qin, A. and Dai, K. (2014) Dioscin inhibits osteoclast differentiation and bone resorption though down-regulating the Akt signaling cascades. Biochem. Biophys. Res. Commun. 443, 658-665 CrossRef PubMed
24. Li, H., Zhai, Z., Liu, G., Tang, T., Lin, Z., Zheng, M., Qin, A. and Dai, K. (2013) Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways. Biochem. Biophys. Res. Commun. 430, 951-956 CrossRef PubMed
25. Thompson, D.D., Simmons, H.A., Pirie, C.M. and Ke, H.Z. (1995) FDA Guidelines and animal models for osteoporosis. Bone 17, 125S-133S CrossRef PubMed
26. Bouxsein, M.L., Boyd, S.K., Christiansen, B.A., Guldberg, R.E., Jepsen, K.J. and Muller, R. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J. Bone Miner. Res. 25, 1468-1486 CrossRef PubMed
27. Cano, E., Hazzalin, C.A. and Mahadevan, L.C. (1994) Anisomycin-activated protein kinases p45 and p55 but not mitogen-activated protein kinases ERK-1 and -2 are implicated in the induction of c-fos and c-jun. Mol. Cell. Biol. 14, 7352-7362 PubMed
28. Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E.A., Ahmad, M.F., Avruch, J. and Woodgett, J.R. (1994) The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369, 156-160 CrossRef PubMed
29. Sanchez, I., Hughes, R.T., Mayer, B.J., Yee, K., Woodgett, J.R., Avruch, J., Kyriakis, J.M. and Zon, L.I. (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. Nature 372, 794-798 CrossRef PubMed
30. Jacobs, C., Ng, T., Ong, M. and Clemons, M. (2014) Long-term benefits versus side-effects from bone-targeted therapies for cancer patients: minimizing risk while maximizing benefits. Curr. Opin. Support. Palliat. Care 8, 420-428 CrossRef PubMed
31. Costa, L. (2014) Bisphosphonates in adjuvant setting for breast cancer: a review of the meta-analysis of bisphosphonates' effects on breast cancer recurrence presented in December 2013 at San Antonio Breast Conference. Curr. Opin. Support. Palliat. Care 8, 414-419 CrossRef PubMed
32. Feng, X. (2005) RANKing intracellular signaling in osteoclasts. IUBMB Life 57, 389-395 CrossRef PubMed
33. Boyle, W.J., Simonet, W.S. and Lacey, D.L. (2003) Osteoclast differentiation and activation. Nature 423, 337-342 CrossRef PubMed
34. Huang, H., Chang, E.J., Ryu, J., Lee, Z.H., Lee, Y. and Kim, H.H. (2006) Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem. Biophys. Res. Commun. 351, 99-105 CrossRef PubMed
35. Ikeda, F., Nishimura, R., Matsubara, T., Tanaka, S., Inoue, J., Reddy, S.V., Hata, K., Yamashita, K., Hiraga, T., Watanabe, T. et al. (2004) Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114, 475-484 CrossRef PubMed
36. Ikeda, F., Matsubara, T., Tsurukai, T., Hata, K., Nishimura, R. and Yoneda, T. (2008) JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts. J. Bone Miner. Res. 23, 907-914 CrossRef PubMed
37. Kim, K.H., Lee, H.J., Jeong, S.J., Lee, H.J., Lee, E.O., Kim, H.S., Zhang, Y., Ryu, S.Y., Lee, M.H., Lu, J. and Kim, S.H. (2011) Galbanic acid isolated from Ferula assafoetida exerts in vivo anti-tumor activity in association with anti-angiogenesis and anti-proliferation. Pharm. Res. 28, 597-609 CrossRef PubMed
38. Pandey, M.K., Kale, V.P., Song, C., Sung, S.S., Sharma, A.K., Talamo, G., Dovat, S. and Amin, S.G. (2014) Gambogic acid inhibits multiple myeloma mediated osteoclastogenesis through suppression of chemokine receptor CXCR4 signaling pathways. Exp. Hematol. 42, 883-896 CrossRef PubMed